________________________________________________________________________________________________________________________
How Evergen combines world-class biomaterials with a patient-first mindset to solve challenges within regenerative medicine
As a world-class global contract development and manufacturing organization( CDMO), Evergen works closely with innovators and OEMs to develop and deliver life-changing regenerative medicine technologies. Prioritizing patients, Evergen’ s innovation begins by identifying complex challenges, then manufacturing solutions that promote healing, accelerate recovery and help prevent complications to enhance patients’ lives.
The company began in 1998 as a spinoff of the University of Florida Tissue Bank but has since expanded its biomaterials capabilities through several acquisitions. Today, Evergen provides customized services with high-quality allograft and xenograft biomaterials, specializing in the growing clinical segments of plastic and reconstructive surgery, sports medicine and orthopedics, neuro / spine, and cardiac. In 2024, Evergen rebranded from RTI Surgical to better reflect the strategic evolution of the company into regenerative medicine. Under its new brand, the company has strengthened its commitment to understanding patient needs and developing customized solutions in high-growth clinical segments.
Kevin Breeden, COO, explains more about Evergen and how its solutions enhance patients’ lives.“ Our customers range from large blue-chip companies, to challengers and innovators in our respective markets,” he opens.“ As we have a diverse customer base, they have varying needs; some might need a biomaterial solution, others need outsourced
248